PAR Price sensitive 15 May 2025, 8:24 AM

PAR Receives US Ethics Approval for Phase 3

Paradigm Biopharmaceuticals Ltd

Sign in to open PDF

No summary is available for this announcement — sign in to read the PDF in full.

Sign in for more about this company, including guidance changes and other insights.
Sign in